MET alterations in advanced non-small cell lung cancer
- PMID: 36924573
- DOI: 10.1016/j.lungcan.2023.02.018
MET alterations in advanced non-small cell lung cancer
Abstract
Targeting the MET pathway in advanced NSCLC has been of particular interest due to its role as both a primary oncogenic driver and secondary oncogenic driver of acquired resistance. Activation of the MET pathway can occur through several mechanisms, which can complicate the diagnostic and treatment approach. Recently, several MET-directed therapies have been developed with promising results. In this narrative review, we summarize the biology and mechanism of MET as a clinically relevant driver mutation, distinct MET alterations including diagnostic challenges, significance in the setting of acquired resistance, and novel treatment strategies in advanced NSCLC.
Keywords: MET alterations; MET amplification; MET exon 14 skipping; MET overexpression; NSCLC.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
- Miscellaneous
 
        